Biohaven misses EPS but beats revenue estimates
Biohaven reports Q1 2026 results with non-GAAP EPS -0.88 (+59% YoY) and revenue $267,400, misses EPS but beats revenue estimates
- Biohaven completed enrollment in its Phase 2 obesity study and plans mid-2026 pivotal BHV-1300 and BHV-1400 trials.
- Company expects multiple pivotal and topline readouts across its pipeline in the second half of 2026.
- First-quarter 2026 results showed a reduced net loss for the company.
- Biohaven reported cash of $351.8 million at quarter end in its first-quarter 2026 update.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.